Apellis Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell APLS and other ETFs, options, and stocks.

About APLS

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. Its products include EMPAVELI and SYFOVRE. 

CEO
Cedric Francois
CEOCedric Francois
Employees
739
Employees739
Headquarters
Waltham, Massachusetts
HeadquartersWaltham, Massachusetts
Founded
2009
Founded2009
Employees
739
Employees739

APLS Key Statistics

Market cap
2.30B
Market cap2.30B
Price-Earnings ratio
109.16
Price-Earnings ratio109.16
Dividend yield
Dividend yield
Average volume
1.91M
Average volume1.91M
High today
$18.59
High today$18.59
Low today
$17.84
Low today$17.84
Open price
$18.43
Open price$18.43
Volume
529.80K
Volume529.80K
52 Week high
$30.48
52 Week high$30.48
52 Week low
$16.10
52 Week low$16.10

Stock Snapshot

Apellis Pharmaceuticals(APLS) stock is priced at $17.98, giving the company a market capitalization of 2.3B. It carries a P/E multiple of 109.16.

During the trading session on 2026-03-18, Apellis Pharmaceuticals(APLS) shares reached a daily high of $18.59 and a low of $17.84. At a current price of $17.98, the stock is +0.8% higher than the low and still -3.3% under the high.

Trading activity shows a volume of 529.8K, compared to an average daily volume of 1.91M.

The stock's 52-week range extends from a low of $16.10 to a high of $30.48.

The stock's 52-week range extends from a low of $16.10 to a high of $30.48.

APLS News

Simply Wall St 2d
Does Apellis Pharmaceuticals' New Board Member Reveal a Deeper R&D Commercialization Strategy Shift?

Apellis Pharmaceuticals recently added Mikael Dolsten, M.D., Ph.D., former chief scientific officer of Pfizer, to its board of directors, bringing decades of hi...

Does Apellis Pharmaceuticals' New Board Member Reveal a Deeper R&D Commercialization Strategy Shift?

Analyst ratings

65%

of 23 ratings
Buy
65.2%
Hold
30.4%
Sell
4.3%

People also own

Based on the portfolios of people who own APLS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.